Synapse

← Petar Seferović

Papers by Petar Seferović

Page 2 · newest first

  1. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failureAmerican Heart Journal · 2023
  2. Incidence, Risk Assessment and Prevention of Sudden Cardiac Death in CardiomyopathiesEuropean Journal of Heart Failure · 2023
  3. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus reportInternational Journal of Cardiology · 2023
  4. Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress Using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESCEuropean Journal of Heart Failure · 2023
  5. Diagnosis and Management of Patients with Left Ventricular Hypertrophy: Role of Multimodality Cardiac Imaging. A Scientific Statement of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2023
  6. Decongestion Strategies In Patients Presenting with Acutely Decompensated Heart Failure: A Worldwide Survey Among PhysiciansEuropean Journal of Heart Failure · 2023
  7. State-of-the-Art Document on Optimal Contemporary Management of CardiomyopathiesEuropean Journal of Heart Failure · 2023
  8. Prevalence, Clinical Characteristics and Outcomes of Heart Failure Patients with or Without Isolated or Combined Mitral and Tricuspid Regurgitation: An Analysis from the ESC-HFA Heart Failure Long-Term RegistryEuropean Journal of Heart Failure · 2023
  9. International validation of the Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) score in heart failureEuropean Journal of Preventive Cardiology · 2023
  10. Acute Heart Failure and Valvular Heart Disease: A Scientific Statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of CardiologyEuropean Journal of Heart Failure · 2023
  11. Prevalence, Characteristics and Prognostic Impact of Aortic Valve Disease in Patients with Heart Failure and Reduced, Mildly Reduced, and Preserved Ejection Fraction: An Analysis of the ESC Heart Failure Long-Term RegistryEuropean Journal of Heart Failure · 2023
  12. Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionEuropean Journal of Heart Failure · 2023
  13. Pre-Discharge and Early Post-Discharge Management of Patients Hospitalized for Acute Heart Failure: A Scientific Statement by the Heart Failure Association of the ESCEuropean Journal of Heart Failure · 2023
  14. Comprehensive characterization of non-cardiac comorbidities in acute heart failure: an analysis of ESC-HFA EURObservational Research Programme Heart Failure Long-Term RegistryEuropean Journal of Preventive Cardiology · 2023
  15. Hyponatraemia and Changes in Natraemia During Hospitalization for Acute Heart Failure and Associations with In-Hospital and Long-Term Outcomes – from the ESC-HFA EORP Heart Failure Long-Term RegistryEuropean Journal of Heart Failure · 2023
  16. Worsening of Chronic Heart Failure: Definition, Epidemiology, Management and Prevention. A Clinical Consensus Statement by the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2023
  17. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure SocietyEuropean Journal of Heart Failure · 2023
  18. Consensus on the assessment of systemic sclerosis–associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessmentJournal of Scleroderma and Related Disorders · 2023
  19. Inotropic Therapy in Patients with Advanced Heart Failure. A Clinical Consensus Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2023
  20. Heart Failure Association/European Society of Cardiology Atlas second edition: new insights into understanding the burden of heart failureEuropean Heart Journal · 2022
  21. Haemodynamic determinants of quality of life in chronic heart failureBMC Cardiovascular Disorders · 2022
  22. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2022
  23. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of CardiologyEuropean Journal of Heart Failure · 2022
  24. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetesCardiovascular Diabetology · 2022
  25. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trialEuropean Journal of Heart Failure · 2022
  26. Impact Analysis of Heart Failure Across European Countries: An ESC-HFA Position PaperESC Heart Failure · 2022
  27. Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular ImagingEuropean Heart Journal - Cardiovascular Imaging · 2022
  28. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter‐defibrillator for primary prevention?European Journal of Heart Failure · 2022
  29. Head‐to‐head comparison between recommendations by the ESC and ACC / AHA / HFSA heart failure guidelinesEuropean Journal of Heart Failure · 2022
  30. Medical Treatment of Heart Failure with Reduced Ejection Fraction in the ElderlyCardiac failure review · 2022
  31. Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2022
  32. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2022
  33. Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart)European Heart Journal · 2022
  34. Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2022
  35. Global burden of heart failure: a comprehensive and updated review of epidemiologyCardiovascular Research · 2022
  36. Education and certification on heart failure of the H eart F ailure A ssociation of the E uropean S ociety of C ardiologyEuropean Journal of Heart Failure · 2022
  37. European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2022
  38. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive CardiologyEuropean Journal of Heart Failure · 2022
  39. Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)European Journal of Heart Failure · 2021
  40. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term RegistryEuropean Journal of Heart Failure · 2021
  41. Feasibility of the cardiac output response to stress test in suspected heart failure patientsFamily Practice · 2021
  42. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fractionEuropean Journal of Heart Failure · 2021
  43. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fractionEuropean Journal of Heart Failure · 2021
  44. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosisCardiovascular Research · 2021
  45. Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of CardiologyEuropean Heart Journal · 2021
  46. Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fractionEuropean Journal of Heart Failure · 2021
  47. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and managementCardiovascular Diabetology · 2021
  48. ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure managementEuropean Heart Journal · 2021
  49. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definitionJournal of Scleroderma and Related Disorders · 2021
  50. COVID ‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure · 2021